Nuclear proteins of hela cells: potential autoantigenic substrate for antinuclear antibodies screening

Main Article Content

Thiha Thway
Sucheewa Wongwai
Prinya Prasongdee
Chanvit Leelayuwat
Amonrat Jumnainsong

Abstract

Antinuclear antibodies (ANA) are important in diagnosis and follow-up of patients with autoimmune conditions. The current increase in ANA requests is driven by broadening the use of ANA from a test for lupus to a test for diverse autoimmune diseases, but the standard method is protracted, cumbersome and prone to error. Therefore, simple and reliable testing are needed and autoantigen substrates are required for the development to capture the autoantibodies. This study evaluates the nuclear proteins of Hela cells (NP-HL) as screening marker for systemic autoimmune diseases. Reactivity of 38 ANA positive and 10 negative sera, against NP-HL was determined by western blotting. We demonstrated that NP-HL reacts with 37 ANA positive sera (97%), and without showing any reaction with negative ones. NP-HL was shown to have a diagnostic value as a screening marker for ANA and, therefore, is a suitable alternative substrate for a new antibody test. This research implies that the NP-HL provides a potential to be used as autoantigen substrate in the rapid testing to define ANA for screening of autoimmune diseases.

Article Details

How to Cite
1.
Thway T, Wongwai S, Prasongdee P, Leelayuwat C, Jumnainsong A. Nuclear proteins of hela cells: potential autoantigenic substrate for antinuclear antibodies screening. Arch AHS [Internet]. 2023 Jul. 17 [cited 2024 May 28];35(2):12-8. Available from: https://he01.tci-thaijo.org/index.php/ams/article/view/261650
Section
Original article

References

Abbas AK, Lichtman AH. Basic immunology: Functions and disorders of the immune system. 2nd ed. Philadelphia, Pa: Elsevier Saunders; 2006.

Playfair JHL, Lydyard PM. Medical immunology made memorable. 2nd ed. London: Churchill Livingstone; 2000.

Lerner A, Jeremias P, Matthias T. The world incidence and prevalence of autoimmune diseases is increasing Int J Celiac Dis 2016; 3(4):151–5.

Mackay IR, Rose NR. The Autoimmune Diseases. 5th ed. Philadelphia, Pa : Elsevier; 2013.

von Mühlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995; 24(5): 323–58.

Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25(11): 1271–7.

Steiner G, Smolen J. Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res 2002; 4(Suppl 2): S1-5.

Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 2014; 73(1): 17–23.

Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis 2010; 69(8): 1420–2.

Pisetsky DS. Antinuclear antibody testing — misunderstood or misbegotten? Nat Rev Rheumatol 2017; 13(8):495–502.

Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum 1997; 40(9): 1601–11.

Emlen W, O’Neill L. Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum 1997; 40(9): 1612–8.

Homburger HA, Cahen YD, Griffiths J, Jacob GL. Detection of antinuclear antibodies: comparative evaluation of enzyme immunoassay and indirect immunofluorescence methods. Arch Pathol Lab Med 1998; 122(11): 993–9.

Chan EKL, Damoiseaux J, Carballo OG, Conrad K, de Melo Cruvinel W, Francescantonio PLC, et al. Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014-2015. Front Immunol 2015; 6: 412-9.

Hoffman IEA, Peene I, Veys EM, De Keyser F. Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests. Clin Chem 2002; 48(12): 2171–6.

Konstantinov KN, Tzamaloukas A, Rubin RL. Detection of autoantibodies in a point-of-care rheumatology setting. Autoimmunity Highlights 2013; 4(2): 55-61.

Bizzaro N, Antico A, Platzgummer S, Tonutti E, Bassetti D, Pesente F, et al. Automated antinuclear immunofluorescence antibody screening: A comparative study of six computer-aided diagnostic systems. Autoimmunity Reviews 2014; 13: 292–8.

Mathiaux F, Barrot A, Elong C, Parent X. Evaluation of an automated system of immunofluorescence analysis in daily practice. Ann Biol Clin (Paris) 2018; 76: 407–15.